Tigecycline MRA InChi: InChI=1S/C20H22F2N4O2S/c1-25(28-2)19(27)26-20(11-6-12-23

InChi: InChI=1S/C20H22F2N4O2S/c1-25(28-2)19(27)26-20(11-6-12-23

a component of fungal cell walls

so that blood volume decreases and urine volume increases

Stimulation of Electroporation-Induced Inward Currents in Glioblastoma Cell Lines by the Heat Shock Protein Inhibitor AUY922

Tigecycline MRA InChi: InChI=1S/C20H22F2N4O2S/c1-25(28-2)19(27)26-20(11-6-12-23Tigecycline is a glycylcycline antibiotic developed by Francis Tally and marketed by Wyeth under the brand name Tygacil. It was given a U. S. Food and Drug Administration (FDA) fast track approval and was approved on June 17, 2005. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus and Acinetobacter baumannii. The New Delhi metallo Lactamase multidrug resistant Enterobacteriaceae